Author | Dylann Cohn-Emery


T-DM1 Shows Activity in HER2+ Metastatic Breast Cancer and Brain Metastases

July 11, 2020


An exploratory analysis of trastuzumab emtansine demonstrated activity and tolerability in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases participating in the prospective KAMILLA trial.

HEPANOVA Trial Update: Final Patient With HCC Enrolled to Receive TTFields/Sorafenib

July 09, 2020


The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.

Community Practice Mergers and Acquisitions Rise Steeply Over 2 Years, COA Report Reveals

July 03, 2020


"Since 2008, 1748 community oncology clinics and/or practices have closed, been acquired by hospitals, undergone corporate mergers, or reported financial difficulties."

Taletrectinib Shows Preliminary Efficacy in Crizotinib-Refractory ROS1+ NSCLC

June 26, 2020


"Taletrectinib is a promising oral tyrosine kinase inhibitor highly selective for ROS1/NTRK mutations with potent activity against ROS1 resistance mutations like G2032R."